If your primary problem is metabolic insulin resistance, weight, irregular ovulation metformin (or a GLP-1) addresses the engine and may also reduce androgens enough on its own
I think that once Mounjaro is approved for weight loss at the end of 2023 this trend will gain steam in a significant way, which would likely reflect in Q2-Q3 2024 earnings for PHG, RMD etc
Compounded medications are not FDA-approved finished products, and suitability is determined by a licensed provider
Of course, challenges can arise, and not every experience will mirror Sarahs
So its pretty likely that theres not going to be a real effect on these other modalities, at least in the initial treatment phase. Dasgupta hopes to see GLP-1s used alongside current treatments, like CPAP